Severe phenytoin intoxication in a subject homozygous for CYP2C9*3
暂无分享,去创建一个
E. Spina | M. G. Scordo | R. Padrini | E Spina | R Padrini | M G Scordo | M Gusella | R Brandolese | M. Gusella | R. Brandolese
[1] E. Yukawa,et al. The Effects of Genetic Polymorphisms of CYP2C9 and CYP2C 19 on Phenytoin Metabolism in Japanese Adult Patients with Epilepsy: Studies in Stereoselective Hydroxylation and Population Pharmacokinetics , 1998, Epilepsia.
[2] S. Higuchi,et al. Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. , 2000, Therapeutic drug monitoring.
[3] G R Wilkinson,et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. , 1994, The Journal of biological chemistry.
[4] M. Ingelman-Sundberg,et al. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. , 1999, Biochemical and biophysical research communications.
[5] J. Miners,et al. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.
[6] J. Brockmöller,et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. , 1999, British journal of clinical pharmacology.
[7] J. Miners,et al. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. , 1993, The Biochemical journal.
[8] G. Aithal,et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications , 1999, The Lancet.
[9] M C Meyer,et al. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. , 1999, Pharmacogenetics.
[10] W. Trager,et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. , 1997, Pharmacogenetics.
[11] G. Shenfield,et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. , 1996, Pharmacogenetics.
[12] T. Inaba. Phenytoin: pharmacogenetic polymorphism of 4'-hydroxylation. , 1990, Pharmacology & therapeutics.
[13] K. Furusho,et al. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy , 1997, Clinical pharmacology and therapeutics.